Novel trial designs for monotherapy.

Area of Science:

• Neurology
• Clinical Pharmacology
• Regulatory Science

Background:

• Licensing novel antiepileptic drugs (AEDs) for drug-naïve epilepsy patients requires specific regulatory trial programs.
• Regulatory approaches in the US (FDA) and Europe (EMA) differ significantly for these trials.

Purpose of the Study:

• To discuss the advantages and disadvantages of current FDA and EMA trial designs for new AEDs.
• To explore novel trial designs that could satisfy both American and European regulatory authorities.

Main Methods:

• Comparative analysis of FDA's withdrawal to monotherapy data with historical controls versus EMA's head-to-head randomized studies.
• Exploration of alternative trial designs, focusing on placebo-controlled studies after a single seizure with EEG/imaging support.

Main Results:

• FDA requires superiority data against historical controls, while EMA accepts non-inferiority data against established comparators.
• Current designs present challenges for drug developers seeking simultaneous approval.

Conclusions:

• There is a need for harmonized or adaptable trial designs to streamline the approval process for new antiepileptic drugs.
• Novel approaches, such as carefully selected placebo-controlled studies, may offer a viable path to satisfy diverse regulatory requirements.